2003:

December 18, 2003
FibroGen Initiates Open-Label, Phase 1 Clinical Trial of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis

November 12, 2003
FibroGen Announces Abstracts on Connective Tissue Growth Factor to be Presented at the 2003 Meeting of the American Society of Nephrology

August 11, 2003
FibroGen Appoints Claire J. Lockey, Vice President, Regulatory Affairs

July 21, 2003
FibroGen Announces Positive Results From First Clinical Trial of Recombinant Human Gelatin

July 9, 2003
FibroGen Receives National Cancer Institute Grant to Develop New Cancer Therapies Targeting Connective Tissue Growth Factor

January 22, 2003
FibroGen Appoints David Y. Liu, Ph.D., Vice President, Research

2002:

April 23, 2002
FibroGen, Inc. Signs on Former Genentech Executive

2001:

September 11, 2001
FibroGen, Inc. and Sankyo Co. Ltd. Announce Research and Development Collaboration

May 2, 2001
FibroGen Awarded R&D Grant from the NIH

January 18, 2001
Aventis Pasteur and FibroGen Sign Strategic Vaccine Agreement

. . . to 2000 press releases